The Li Ka Shing Institute of Virology was created in 2010 through the combined gifts of $25-million from the Li Ka Shing (Canada) Foundation and $52.5-million from the Government of Alberta and incorporates researchers from the Alberta Institute for Viral Immunology and the Centre of Excellence for Viral Hepatitis Research.
This entity brings together clinicians and basic scientists to study the development of hepatitis vaccines and antiviral therapies, animal models and cell culture models, genetic based population studies, epidemiological studies of populations at risk, and programs to reduce fatal outcomes of viral hepatitis infection.
The AIVI was created in 2008 through joint funding from the Alberta Government (Advanced Education and Technology) and the Canadian Foundation for Innovation (CFI). Our new building and core facilities are nearing completion. Contact information and travel directions to the university are available through the home pagemenu. More content will be added as the AIVI takes shape. AIVI Proposal. AIVI is an organization that links together Alberta-based virologists and immunologists. It gained its initial impetus from a 2006 $24.9 million Canadian Foundation for Innovation (CFI) award and was granted formal institute status by the University of Alberta’s General Faculties Council in 2007. AIVI Infrastructure is currently being designed and built at the University of Alberta and the University of Calgary. The University of Alberta is the lead for this project and in Edmonton the new facilities we are building include a BSL3-level animal biocontainment suite (available2011), new siRNA robotics, imaging, and other core facilities (operational), and a BSL-2 animal biocontainment suite (March 2011). These facilities will provide biosafe and biosecure laboratory space that will greatly facilitate research involving infectious agents.
The research interests of LKSIOV faculty members encompass viral pathogenesis,
vaccine development, correlates of immunity, enhancement of vaccine efficacy and
novel viral therapeutics with expertise in:
• Influenza viruses
• Pox viruses
• Hepatitis B and C viruses
• Rubella virus
• West Nile Virus
• Dengue Virus